Edition:
United Kingdom

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

28.15USD
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
$28.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
117,652
52-wk High
$37.55
52-wk Low
$2.70

Chart for

About

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $362.06
Shares Outstanding(Mil.): 24.97
Dividend: --
Yield (%): --

Financials

  MRTX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -3.43 -- --
ROI: -91.06 1.58 14.38
ROE: -91.23 2.41 16.07

BRIEF-Mirati Therapeutics Q4 Loss Per Share $0.67

* MIRATI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region

* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION

08 Jan 2018

BRIEF-Mirati announces advancement of opportunities with inhibitor programs

* Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs

13 Nov 2017

BRIEF-Mirati Therapeutics reports Q3 loss per share of $0.65

* Mirati Therapeutics reports third quarter 2017 financial results

01 Nov 2017

Earnings vs. Estimates